economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Galdermas

Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership OG_NewsReleaseCompanyLogo_93254.jpg

Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

creativebharatgroup@gmail.com January 23, 2025
Zug, Switzerland:   Galderma will present new data on Relfydess (RelabotulinumtoxinA) –...
Read More Read more about Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union OG_NewsReleaseCompanyLogo_92866.jpg

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

creativebharatgroup@gmail.com December 13, 2024
Zug, Switzerland:   Atopic dermatitis is a common, chronic, and flaring inflammatory...
Read More Read more about CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis OG_NewsReleaseCompanyLogo_92678.jpg

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

creativebharatgroup@gmail.com November 29, 2024
Zug, Switzerland:   Full results from the phase III OLYMPIA 1 trial...
Read More Read more about Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis